

ANTIDEPRESSANTS, OTHER PRIOR AUTHORIZATION FORM

Prior authorization guidelines for **Antidepressants**, **Other** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx.

		-			
☐New request ☐Renewal request	# of pages:	Prescriber name:			
Name of office contact:		Specialty:			
Contact's phone number:		NPI:	State License #:	State License #:	
LTC facility contact/phone:		Street address:			
Beneficiary name:		City/state/zip:			
Beneficiary ID#:	DOB:	Phone:	Fax:		
CLINICAL INFORMATION					
Drug requested: Strength:		Dosage form:			
Dose/directions:			Quantity:	Refills:	
Diagnosis (submit documentation):			Dx code (<u>required</u>):		
Has the beneficiary taken the requested non-preferred medication within the past 90 days?			☐Yes ☐No Submit documentation.		
Does the beneficiary have a history of trial and failure of or a contraindication or an intolerance to the preferred Antidepressants, Other taken at maximally tolerated doses for at least 6 weeks? Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred agents in this class.			☐Yes Submit documentation.		
Does the beneficiary have a history of trial and failure of or a contraindication or an intolerance to any of the SSRI antidepressants taken at maximally tolerated doses for at least 6 weeks? Check all that apply. Citalopram (e.g., Celexa)			☐Yes Submit documentation.		
Does the beneficiary have a history of trial and failure of or a contraindication or an intolerance to augmentation therapy (e.g., lithium, an antipsychotic, a stimulant agent) in combination with an antidepressant at maximally tolerated doses for at least 6 weeks?			☐Yes Submit documentation.		
For Spravato: Does the beneficiary meet all of the following? Check all that apply. Is prescribed Spravato by or in consultation with a psychiatrist Will use Spravato in conjunction with a therapeutic dose of an oral antidepressant Does not have severe hepatic impairment (Child-Pugh class C) For renewal requests for Spravato: Experienced improvement in disease severity since starting treatment with Spravato			☐Yes Submit documentation.		
PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION Describer Signatures					
Prescriber Signature:			Date:		

<u>Confidentiality Notice</u>: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.